PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Phase 2
34
about 5.1 years
18+
Male only
1 site in FL
What this study is about
This trial is testing whether giving radiation therapy to the para-aortic and pelvic lymph nodes, along with androgen suppression treatment, improves control of prostate cancer. The goal is also to preserve quality of life after radiation therapy and use PSMA PET/CT scans to manage disease progression.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Para Aortic Radiation Therapy: Photon Therapy
- 2.Receive Para Aortic Radiation Therapy: Proton Therapy
- 3.Take Androgen Deprivation Therapy
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
hormone therapy
Primary: Progression-free Survival (PFS)
Secondary: Change in Quality of Life Scores: EPIC 26 Short Form, Change in Quality of Life Scores: HADS, Change in Quality of Life Scores: IPSS, Complete Early Response Rate, Metastasis-Free Survival, Overall Survival (OS), Proportion of Participants Experiencing Cumulative Late Grade ≥ 2 Treatment-Related Toxicity
radiation
Oncology